MBT-2/VEGFR-2 RNA-transfected autologous dendritic cell vaccine (Duke University)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameMBT-2/VEGFR-2 RNA-transfected autologous dendritic cell vaccine (Duke University)
Drug Alias Namemurine bladder tumor 2/vascular endothelial growth factor receptor 2 RNA-transfected autologous dendritic cell vaccine (Duke University)
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine
Mechanisms of ActionVascular endothelial growth factor receptor stimulants
TargetsVascular endothelial growth factor receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDuke University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDuke University
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A